Fax: (011) 49-621-383-3833
Response and resistance in 300 patients with BCR-ABL–positive leukemias treated with imatinib in a single center
A 4.5-year follow-up
Version of Record online: 3 MAR 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 8, pages 1659–1669, 15 April 2005
How to Cite
Lahaye, T., Riehm, B., Berger, U., Paschka, P., Müller, M. C., Kreil, S., Merx, K., Schwindel, U., Schoch, C., Hehlmann, R. and Hochhaus, A. (2005), Response and resistance in 300 patients with BCR-ABL–positive leukemias treated with imatinib in a single center. Cancer, 103: 1659–1669. doi: 10.1002/cncr.20922
- Issue online: 4 APR 2005
- Version of Record online: 3 MAR 2005
- Manuscript Accepted: 3 DEC 2004
- Manuscript Revised: 21 NOV 2004
- Manuscript Received: 13 OCT 2004
- Novartis Pharma, Nürnberg, Germany
- German Bundesministerium für Bildung und Forschung. Grant Number: DLR e.V.-01 GI9980/6
- European LeukemiaNet
- chronic myeloid leukemia;
- clinical strategies;
- hematologic resistance
The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods.
The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL–positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
In CP, hematologic remission was achieved in 97% and major (MCR) and complete cytogenetic remission (CCR) in 61% and 49% of patients, respectively. The chance to achieve MCR was higher in patients commencing imatinib earlier in the course of CML. In AP, the median survival period after the start of imatinib was 44 months, and MCR and CCR were observed in 31% and 26% of patients, respectively. In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively. Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.
The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy. Cancer 2005. © 2005 American Cancer Society.